Topical 2.0% Dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium: YAG laser posterior capsulotomy

Archives of Ophthalmology

Volumn 115, Issue 10, 1997, Pages 1241-1244

  Ladas, Ioannis D ^a,b   Baltatzis, Stefanos ^a   Panagiotidis, Dimitris ^a   Zafirakis, Panagiotis ^a   Kokolakis, Stefanos N ^a   Theodossiadis, George P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DORZOLAMIDE; PLACEBO;

ADULT; AGED; ARTICLE; CAPSULOTOMY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRACAPSULAR CATARACT EXTRACTION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEODYMIUM LASER; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 9844236480     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1997.01100160411003     Document Type: Article

References (39)

1. Terry AC, Stark WJ, Maumenee AE, Fagadau W. Neodymium YAG laser for posterior capsulotomy. Am J Ophthalmol. 1983;96:716-720.
2. Channell MM, Beckman H. Intraocular pressure changes after neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 1984;102:1024-1026.
3. Parker WT, Clorfeine GS, Stoclin RD. Marked intraocular pressure rise following Nd-YAG laser capsulotomy. Ophthalmic Surg Lasers. 1984;15:103-104.
4. Vine AK. Ocular hypertension following Nd:YAG laser capsulotomy: a potentially blinding complication. Ophthalmic Surg Lasers. 1984;15:360-363.
5. Kraff MC, Sanders DR, Lieberman HL. Intraocular pressure and the corneal endothelium after neodymium-YAG laser posterior capsulotomy: relative effects of aphakia and pseudophakia. Arch Ophthalmol. 1985;103:511-514.
6. Stark WJ, Worhten D, Holladay JT, Murray G. Neodymium:YAG lasers: an FDA report. Ophthalmology. 1985;92:209-212.
7. Flohr MJ, Robin AL, Kelley JS. Early complications following Q-switched neodymium-YAG laser capsulotomy. Ophthalmology. 1985;92:360-363.
8. Richter CU, Arzeno G, Pappas HR, Steinert RF, Puliafito C, Epstein DL. Intraocular pressure elevation following Nd:YAG laser posterior capsulotomy. Ophthalmology. 1985;92:636-640.
9. Slomovic AR, Parrish RK. Acute elevations of intraocular pressure following Nd: YAG laser posterior capsulotomy. Ophthalmology. 1985;92:973-976.
10. Nirankari VS, Richards RD. Complications associated with the use of the neodymium-YAG laser. Ophthalmology. 1985;92:1371-1375.
11. Blackwell C, Hirst LW, Kinnas SJ. Neodymium-YAG laser capsulotomy and potential blindness. Am J Ophthalmol. 1984;98:521-522.
12. Kurata F, Krupin T, Sinclair S, Kapp L. Progressive glaucomatous visual field loss after neodymium-YAG laser posterior capsulotomy. Am J Ophthalmol. 1984;98:632-634.
13. Richter CU, Arzeno G, Pappas HR, Arrigg CA, Wasson P, Steinert RF, Prevention of intraocular pressure elevation following neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 1985;103:912-915.
14. Brown SVL, Thomas JV, Belcher DC, Simmons RJ. Effect of pilocarpine in treatment of intraocular pressure elevation following neodymium-YAG laser posterior capsulotomy. Ophthalmology. 1985;92:354-359.
15. Stilma JS, Boen-Tann IN. Timolol and intra-ocular pressure elevation following neodymium:YAG laser surgery. Doc Ophthalmol. 1986;61:233-239.
16. Migliori ME, Beckman H, Channell MM. Intraocular pressure changes after neodymium-YAG laser capsulotomy in eyes pretreated with timolol. Arch Ophthalmol. 1987;105:473-475.
17. Silverstone DE, Novack GD, Kelley EP, Chen KS. Prophylactic treatment of intraocular pressure elevations after neodymium:YAG laser posterior capsulotomles and extracapsular cataract extractions with levobunolol. Ophthalmology. 1988;95:713-718.
18. Pollack IP, Brown RH, Crandall AS, et al. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1 % apraclonidine. Arch Ophthalmol. 1988;106:754-757.
19. Brown RH, Stewart RH, Lynch MG, et al. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Ophthalmology. 1988;95:378-384.
20. Lowenstein A, Varssano D, Lazar M, Geyer O. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical clonidine. Acta Ophthalmol Scand. 1991;69:462-465.
21. Silverstone DE, Brint SF, Olander KW, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies. Am J Ophthalmol. 1992;113:401-405.
22. Culom RD Jr, Schwartz LW. The effect of apraclonidine on intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy. Ophthalmic Surg Lasers. 1993;24:623-626.
23. Rosenberg LF, Krupin T, Ruderman J, et al. Apraclonidine and anterior segment laser surgery: comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. Ophthalmology. 1995;102:1312-1318.
24. Ladas ID, Pavlopoulos GP, Kokolakis SN, Theodossiadls GP. Prophylactic use of acetazolamide to prevent intraocular pressure elevation following Nd:YAG laser posterior capsulotomy. Br J Ophthalmol. 1993;77:136-138.
25. - from plasma to posterior chamber, effect of acetazoiamide and relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1976;15:356-364.
26. Weiner JM. Diuretics and other agents employed in the mobilization of edema fluid. In:Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Macmillan Publishing Co Inc; 1990:716-718.
27. Wang RF, Serle JB, Podos SM, Sugrue MF. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys. Arch Ophthalmol. 1990;108:511-513.
28. Sugrue MF, Mallorga P, Schwam H, Baldwin JJ, Ponticello GS. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res. 1990;9:607-615.
29. Wang RF, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297-1299.
30. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 1991;98:308-312.
31. Kass MA, Laibovitz RA, Lippa EA, et al. Comparative activity of 3% MK-507, a topical CAI, with betaxolol. Invest Ophthalmol Vis Sci. 1991;32(suppl):989. Abstract.
32. Nardin G, Lewis R, Lippa EA, et al. Activity of the topical CAI MK-507 BID when added to timolol bid. Invest Ophthalmol Vis Sci. 1991;32(suppl):989. Abstract.
33. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:495-499.
34. Merck Research Laboratories Clinical Study Report (Synopsis) Multicenter Study A Single-Dose, Randomized, Double-masked, Six-Period Crossover. Ocular Tolerability Comparison Study of L-671,152 (Dorzolamide, MK-507) and MK-417 Ophthalmic Solutions in Healthy Volunteers. West Point, Pa: Merck & Co Inc; 1992;Protocol No. 007.
35. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111:1343-1350.
36. Strahlman ER, Deasy D, Panebianco D, and the Timolol/Dorzolamide Combination Study Group. A 2-week pilot activity study of a fixed combination of timolol and dorzolamide hydrochloride. Invest Ophthalmol Vis Sci. 1993;34(suppl): 1148. Abstract.
37. Lippa EA, Clineschmidt CM, Tipping RW, Strohmaier KM, and the Dorzolamide Dose-Response Study Group. Dorzolamide hydrochloride: 6-week dose-response study of an active topical carbonic anhydrase inhibitor. Invest Ophthalmol Vis Sci. 1993;34(suppl):1149. Abstract.
38. Strahlman E, Tipping R, Vogel R, and the International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113:1009-1016.
39. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM, and the Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology. 1996;103:1283-1293.